E3 ligase Ligand 3, a carboxylic acid-functionalized analog of thalidomide, is a CRBN ligand for E3 Ligase used in PROTAC technology.

CRBN modulator 1 is a thalidomide analog and a CRBN modulator (IC50 = 3.5 μM and Ki = 0.98 μM) disclosed in WO 2020006262.

Lenalidomide-OH, a hydroxylated analog of Lenalidomide which is a cereblon (CRBN) ligand used for E3 ubiquitin ligase, can be used as a E3 ligase ligand in PROTACs for the recruitment of CRBN protein.

E3 ligase Ligand 2, a hydroxylated thalidomide, is a CRBN ligand of E3 ligase which is used in PROTAC technology.

Lenalidomide HCl (formerly CC-5013; CC 5013; IMiD1; trade name Revlimid), the hydrochloride salt of Lenalidomide, is a derivative of thalidomide approved for use in the United States since 2005 in the treatment for myeloma and blood disorders called myelodysplastic syndromes.

VH-298 is a novel and highly potent inhibitor of the VHL:HIF-α protein-protein interaction with a Kd value of 80 to 90 nM, and has been used in PROTAC technology.

E3 ligase Ligand, a fluoronated thalidomide, is a CRBN ligand for E3 Ligase used in PROTAC technology.

E3 ligase Ligand 1 is a novel, potent and selective ligand for E3 Ligase used in PROTAC technology.

(S,R,S)-AHPC-Me (also known as VHL ligand 2 or E3 ligase Ligand 1A) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.

Lenalidomide (Revlimid, CC-5013) is a derivative of thalidomide approved in the United States in 2005 for the treatment for myeloma and blood disorders called myelodysplastic syndromes.